At ASCO, the Cancer Community Hyped the Wrong Trial
Oncologist Bishal Gyawali, MD, PhD, highlights concerns surrounding which trials the oncology community is choosing to celebrate.
Related Articles
Current knowledge of vertebral osteomyelitis: a review
European Journal of Clinical Microbiology & Infectious Diseases – As life expectancy increases worldwide, the elderly population in every country is growing in both the…
Immunotherapy for Early-Stage Triple-Negative Breast Cancer | NEJM
Early-stage triple-negative breast cancers, which lack expression of three proteins (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2), have long been defined…
“Target Trial Emulation” for Observational Studies — Potential and Pitfalls | NEJM
To improve the quality of observational studies, target trial emulation requires careful specification of design elements, analytic methods for addressing confounding, and reporting of sensitivity…
Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies
This case series evaluates whether human leukocyte antigen (HLA) genotype could be inferred from standard next-generation sequencing, comparing concordance with confirmatory whole-exome sequencing and assessing…
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | NEJM
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition…
EARLY BIRD Black Friday 2024 is HERE!
We’re making Black Friday EVEN BETTER with a never before offered EARLY BIRD rate💗 10 Spots total First-come, first-served Offer disappears when all spots are…
Paper: Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
Program: Oral and Poster Abstracts Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Clinical trials, MPN, Drug development,…
The Sexual Side Effects of Hormones and Other Drugs
Medical school may have skipped over the significant consequences of common drugs such as oral contraceptives and finasteride.
Immunotherapy for Early-Stage Triple-Negative Breast Cancer | NEJM
Early-stage triple-negative breast cancers, which lack expression of three proteins (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2), have long been defined…
The Duffy Null Phenotype — Addressing a Source of Discrimination in Cancer Care | NEJM
Cancer research and care practices that adversely affect people with the Duffy null phenotype are an underrecognized and widespread source of discrimination against people of…
